

For Immediate Release

PluroGen Therapeutics, Inc. Announces

New US Patent Issued

For PluroGen's Advanced PluroGel® Biomaterial

Norristown, Pennsylvania 1 November 2014

PluroGen Therapeutics, Inc., leading solutions for wound, burn and skin care with its advanced PluroGel® Biomaterial surfactant products, announced today that it received a new United States patent for its Advanced PluroGel® Biomaterial extending patent protection to 2029.

This new U.S. patent protects the special ability of PluroGen's advanced PluroGel® Biomaterial products to have a positive effect in preventing or dispersing biofilms in wounds and in eliminating bacteria causing biofilms. Biofilm establishment in a wound is thought to prevent wound healing. PluroGel's ability prevent or disperse biofilms and eliminate the bacteria of a biofilm are significant performance features differentiating PluroGel® products and giving them important competitive advantage.

"This is an important new strategic asset for PluroGen adding protection and value for the Company and its shareholders" commented Neal Koller, President and CEO of PluroGen. "PluroGen is growing its intellectual property portfolio."

About PluroGen Therapeutics

PluroGen Therapeutics, Inc. is a biotechnology company that provides clinically advanced topical anti-infective products for diabetic ulcers, chronic (nonhealing) wounds and burns. The company developed its core family of PluroGel® products by utilizing its patent-protected advanced PluroGel® Biomaterial. In working closely with doctors, nurses, patients and healthcare institutions, PluroGel® products have been routinely used with documented superior results on more than 14,000 patients in and outside of the USA. More information can be found on the company web site at www.plurogen.com. For PluroGen Investor Information please call +1 (610) 539-3670.

Safe Harbor Statement:

The statements in the press release that relate to PluroGen's (the company) expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the company's actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.